| Title |
| • The potential public health benefit of live attenuated pertussis vaccines, Expert Opinion on Drug Delivery, Jan. 2026
|
| • Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis, Dec. 2025
|
| • Global Incidence of Pertussis After the COVID-19 Pandemic, JAMA Network, Dec. 2025
|
| • Live attenuated Bordetella pertussis intranasal vaccine (BPZE1). World Vaccine Congress, April 6, 2023
|
| • Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus–diphtheria–acellular pertussis vaccine: a randomised, double-blind, phase 2b trial
|
| • Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study
|
| • Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans
|
| • Livening up pertussis vaccine development
|
| • IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine
|
| • A Phase I Clinical Study of a Live Attenuated Bordetella Pertussis Vaccine - BPZE1; A Single Centre, Double-Blind, Placebo-Controlled, Dose-Escalating Study of BPZE1 Given Intranasally to Healthy Adult Male Volunteers
|
| • B-cell responses after intranasal vaccination with the novel attenuated Bordetella Pertussis vaccine strain BPZE1 in a randomized phase I clinical trial
|
| • Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against Bordetella Pertussis Disease and Infection
|
| • Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice
|
| • New pertussis vaccination approaches: en route to protect newborns?
|
| • Pertussis: acellular, whole-cell, new vaccines, what to choose?
|
| • Live attenuated vaccines against pertussis
|
| • Dose response of attenuated Bordetella Pertussis BPZE1-induced protection in mice
|
| • Live Attenuated B. pertussis as a Single-Dose Nasal Vaccine against Whooping Cough.
|
| • Highly Attenuated Bordetella Pertussis Strain BPZE1 as a Potential Live Vehicle for Delivery of Heterologous Vaccine Candidates
|
| • A Live Attenuated Bordetella Pertussis Candidate Vaccine Does Not Cause Disseminating Infection in Gamma Interferon Receptor Knockout Mice
|
| • T- and B-Cell-Mediated Protection Induced by Novel, Live Attenuated Pertussis Vaccine in Mice. Cross Protection against Parapertussis
|
| • Dual mechanism of protection by live attenuated Bordetella Pertussis BPZE1 against Bordetella bronchiseptica in mice
|
| • Attenuated Bordetella Pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models
|
| • Immunogenicity of Live Attenuated B. pertussis BPZE1 Producing the Universal Influenza Vaccine Candidate M2e
|
| • Attenuated Bordetella Pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism
|
| • A live, attenuated Bordetella Pertussis vaccine provides long-term protection against virulent challenge in a murine model
|
| • Genetic stability of the live attenuated Bordetella Pertussis vaccine candidate BPZE1
|
| • Attenuated Bordetella Pertussis Vaccine Candidate BPZE1 Promotes Human Dendritic Cell CCL21-Induced Migration and Drives a Th1/Th17 Response
|
| • Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1
|
| • Attenuated Bordetella Pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model
|
| • Attenuated Bordetella Pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route
|
| • Possible Options for New Pertussis Vaccines
|
| • Live Attenuated B. pertussis BPZE1 Rescues the Immune Functions of Respiratory Syncytial Virus Infected Human Dendritic Cells by Promoting Th1/Th17 Responses
|
